SCHEMBL5215470

SCHEMBL5215470

O=C(O)c1csc(Nc2ncccc2Cl)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.50
NPC1 O15118 5/20 0.50
KDM1A O60341 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.46
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
HPGD P15428 2/20 0.44
ALOX15 P16050 2/20 0.44
HSD17B10 Q99714 2/20 0.44
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
POLB P06746 1/20 0.43
DHODH Q02127 2/20 0.42
GAA P10253 2/20 0.42
AMY1A P0DUB6 1/20 0.42
MAPT P10636 2/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
GCK P35557 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5216256 0.82 EGFR (0.54) RAB9ANPC1KDM1AL3MBTL1ALDH1A1
SCHEMBL5218680 0.81 KDM1A (0.56) RAB9ANPC1KDM1AL3MBTL1ALDH1A1
SCHEMBL14422263 0.81 MEN1 (0.52) RAB9ANPC1KDM1AL3MBTL1SMN1; SMN2
SCHEMBL14422194 0.79 NPC1 (0.50) RAB9ANPC1KDM1AL3MBTL1ALDH1A1
SCHEMBL798528 0.79 NPC1 (0.77) RAB9ANPC1KDM1AL3MBTL1ALDH1A1
SCHEMBL14422262 0.78 MAPK1 (0.55) KMT2AMEN1MAPTLMNAKDM4E
SCHEMBL2338454 0.77 GCK (0.70) GCK
SCHEMBL525588 0.76 NPC1 (0.61) RAB9ANPC1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL5217553 0.74 L3MBTL1 (0.50) RAB9ANPC1KDM1AL3MBTL1ALDH1A1
SCHEMBL5216059 0.74 NPSR1 (0.44) RAB9ANPC1KDM1AALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 US disclosed
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 US disclosed
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 US disclosed
EP-1818333-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-08-15 EP disclosed
EP-1818333-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-08-15 EP disclosed
EP-1603905-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2005-12-14 EP disclosed
WO-2004072068-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2004-08-26 WO disclosed
US-20040157845-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157845-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 RAB9A 1553/4885NPC1 2453/4885KDM1A 3163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.